FLP
CPRX

Financial Life Planners’s Catalyst Pharmaceutical CPRX Stock Holding History

Financial Life Planners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.6K Buy
+2,124
New +$50.6K 0.04% 114
2025
Q4 		– Sell
-2,124
Closed -$41.8K – 117
2025
Q3 		$41.8K Buy
+2,124
New +$43.7K 0.03% 138

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Financial Life Planners's CPRX Position: Q1 2026 in Review

Financial Life Planners opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 2,124 shares worth $52.6K. The stake represents 0.04% of the portfolio and ranks #114 among its holdings. This is a return to the name: Financial Life Planners previously reported a position in CPRX as recently as Q3 2025.

Financial Life Planners first reported a position in CPRX in Q3 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Financial Life Planners held 2,124 shares of Catalyst Pharmaceutical worth $52.6K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Financial Life Planners position in Q1 2026.
  • Catalyst Pharmaceutical made up 0.04% of Financial Life Planners's portfolio in Q1 2026, its #114 holding.
  • Financial Life Planners first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Financial Life Planners's 13F filing for Q1 2026, filed 24 Apr 2026.